Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

However, some complement components, such as complement 5a (C5a), act as strong mediators of inflammation. Because in some cases inflammation can promote cancer growth, John Lambris at the University ...

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent ...

InflaRx also hosted a lunch seminar focused on C5a/C5aR inhibition in human disease ... our commitment to advancing the science of complement inhibition and progress toward our goal of developing ...

SEOUL, South Korea I June 02, 2025 I ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S.

InflaRx will participate in a panel - Advances in Dermatology: AD and CSU – being held 10:45-11:20 AM ET, as well as participate in one-on-one investor meetings. Leerink Partners Therapeutics Forum: I ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense ...